vs
Side-by-side financial comparison of Aterian, Inc. (ATER) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $15.1M, roughly 1.2× Aterian, Inc.). SCYNEXIS INC runs the higher net margin — 65.7% vs -52.5%, a 118.3% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -38.5%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -13.5%).
Aterian, Inc. is a technology-enabled consumer products company that leverages artificial intelligence and data analytics to identify market demand, develop, source and distribute a wide portfolio of affordable goods spanning home improvement, wellness, personal care, pet supplies and outdoor recreation. It primarily sells its products through leading global e-commerce platforms, with core markets covering North America and Europe.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
ATER vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.1M | $18.6M |
| Net Profit | $-7.9M | $12.3M |
| Gross Margin | 56.1% | — |
| Operating Margin | -51.1% | 56.3% |
| Net Margin | -52.5% | 65.7% |
| Revenue YoY | -38.5% | 1808.5% |
| Net Profit YoY | -512.2% | 376.5% |
| EPS (diluted) | — | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.1M | $18.6M | ||
| Q3 25 | $19.0M | $334.0K | ||
| Q2 25 | $19.5M | $1.4M | ||
| Q1 25 | $15.4M | $257.0K | ||
| Q4 24 | $24.6M | $977.0K | ||
| Q3 24 | $26.2M | $660.0K | ||
| Q2 24 | $28.0M | $736.0K | ||
| Q1 24 | $20.2M | $1.4M |
| Q4 25 | $-7.9M | $12.3M | ||
| Q3 25 | $-2.3M | $-8.6M | ||
| Q2 25 | $-4.9M | $-6.9M | ||
| Q1 25 | $-3.9M | $-5.4M | ||
| Q4 24 | $-1.3M | — | ||
| Q3 24 | $-1.8M | $-2.8M | ||
| Q2 24 | $-3.6M | $-14.5M | ||
| Q1 24 | $-5.2M | $411.0K |
| Q4 25 | 56.1% | — | ||
| Q3 25 | 56.1% | — | ||
| Q2 25 | 54.3% | — | ||
| Q1 25 | 61.4% | — | ||
| Q4 24 | 63.4% | — | ||
| Q3 24 | 60.3% | — | ||
| Q2 24 | 60.4% | — | ||
| Q1 24 | 65.1% | — |
| Q4 25 | -51.1% | 56.3% | ||
| Q3 25 | -10.7% | -2516.5% | ||
| Q2 25 | -23.1% | -701.0% | ||
| Q1 25 | -24.1% | -3350.2% | ||
| Q4 24 | -6.5% | — | ||
| Q3 24 | -6.6% | -1563.6% | ||
| Q2 24 | -11.5% | -1255.0% | ||
| Q1 24 | -26.1% | -692.5% |
| Q4 25 | -52.5% | 65.7% | ||
| Q3 25 | -12.0% | -2572.2% | ||
| Q2 25 | -25.0% | -504.8% | ||
| Q1 25 | -25.4% | -2097.7% | ||
| Q4 24 | -5.3% | — | ||
| Q3 24 | -6.8% | -425.5% | ||
| Q2 24 | -13.0% | -1964.4% | ||
| Q1 24 | -25.5% | 29.9% |
| Q4 25 | — | $0.25 | ||
| Q3 25 | — | $-0.17 | ||
| Q2 25 | — | $-0.14 | ||
| Q1 25 | — | $-0.11 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.06 | ||
| Q2 24 | — | $-0.30 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.9M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.2M | $49.4M |
| Total Assets | $29.6M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.9M | $40.0M | ||
| Q3 25 | $7.6M | $37.9M | ||
| Q2 25 | $10.5M | $44.8M | ||
| Q1 25 | $14.3M | $40.6M | ||
| Q4 24 | $18.0M | $59.3M | ||
| Q3 24 | $16.1M | $68.8M | ||
| Q2 24 | $20.3M | $73.0M | ||
| Q1 24 | $17.5M | $80.2M |
| Q4 25 | $15.2M | $49.4M | ||
| Q3 25 | $22.6M | $36.4M | ||
| Q2 25 | $24.3M | $44.5M | ||
| Q1 25 | $27.0M | $50.5M | ||
| Q4 24 | $30.0M | $55.1M | ||
| Q3 24 | $30.6M | $58.5M | ||
| Q2 24 | $30.9M | $60.4M | ||
| Q1 24 | $33.0M | $74.1M |
| Q4 25 | $29.6M | $59.0M | ||
| Q3 25 | $40.1M | $51.1M | ||
| Q2 25 | $45.4M | $60.7M | ||
| Q1 25 | $49.8M | $67.9M | ||
| Q4 24 | $49.5M | $90.6M | ||
| Q3 24 | $52.1M | $99.0M | ||
| Q2 24 | $59.9M | $107.8M | ||
| Q1 24 | $55.7M | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.0M | $18.4M |
| Free Cash FlowOCF − Capex | $-1.0M | — |
| FCF MarginFCF / Revenue | -6.9% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.0M | $18.4M | ||
| Q3 25 | $-1.6M | $-8.7M | ||
| Q2 25 | $-4.4M | $-7.5M | ||
| Q1 25 | $-3.9M | $-7.5M | ||
| Q4 24 | $-9.0K | $-24.0M | ||
| Q3 24 | $-722.0K | $765.0K | ||
| Q2 24 | $2.9M | $-10.9M | ||
| Q1 24 | $-6.0K | $-4.0M |
| Q4 25 | $-1.0M | — | ||
| Q3 25 | $-1.6M | — | ||
| Q2 25 | $-4.4M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $2.9M | — | ||
| Q1 24 | $-42.0K | — |
| Q4 25 | -6.9% | — | ||
| Q3 25 | -8.4% | — | ||
| Q2 25 | -22.7% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 10.3% | — | ||
| Q1 24 | -0.2% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATER
| Sales Channel Directly To Consumer | $13.1M | 87% |
| Heating Cooling And Air Quality | $2.1M | 14% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
